Lumiracoxib (rINN) is a carboxylic acid COX-2 selective inhibitor non-steroidal anti-inflammatory drug, manufactured by Novartis and still sold in few countries, including Mexico, Ecuador and the Dominican Republic, under the trade name Prexige (sometimes misquoted as \"Prestige\" by the media).

CAS：220991-20-8
中文别名：2-[(2-氯-6-氟苯基)氨基」-5-甲基苯乙酸;鲁米昔布;
英文别名：[14C]-Lumiracoxib;2-(2-((2-chloro-6-fluorophenyl)amino)-5-methylphenyl)acetic acid;Prexige;Joicela;Prexige (Novartis);5-methyl-2-(2\'-chloro-6\'-fluoroanilino)phenylacetic acid;Lumiracoxib;2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-benzeneacetic acid;(2-((2-chloro-6-fluorophenyl)-amino)-5-methylphenyl)-acetic acid;2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid;Lumiracoxib [USAN:INN];COX189;
分子式：C15H13ClFNO2
分子量：293.721
精确质量：293.062
Psa：49.33
Logp：4.2312

UNII：V91T9204HU

外观与性状：淡黄色固体
密度：1.363 g/cm3
沸点：395.7ºC at 760 mmHg
熔点：139-141ºC
闪点：193.1ºC
折射率：1.628
蒸汽压：5.68E-07mmHg at 25°C